Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005

Archives of Internal Medicine

Volumn 168, Issue 7, 2008, Pages 749-755

  Bliss, Sandra J ^a,c   Larzalere Hinton, Francene ^a   Lacapa, Rochelle ^a   Eagle, Kathryn R ^a   Frizzell, Felicia ^a   Parkinson, Alan ^b   Reid, Raymond ^a   Craig, Mariddie ^a   Santosham, Mathuram ^a   O'Brien, Katherine L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS POLYSACCHARIDE;

ADULT; AGED; ALCOHOLISM; AMERICAN INDIAN; ARTICLE; BACTERIUM ISOLATE; CAUSE OF DEATH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; FEMALE; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SEROTYPE; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS INFECTION; VACCINATION;

ADOLESCENT; ADULT; AGED; ALCOHOLISM; ARIZONA; DIABETES COMPLICATIONS; FEMALE; HUMANS; INDIANS, NORTH AMERICAN; LUNG DISEASES; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEX FACTORS; VACCINATION;

EID: 42449114360     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.168.7.749     Document Type: Article

References (37)

1. World Health Organization. Pneumococcal vaccines: WHO position paper. Wkly Epidemiol Rec. 2003;78(14):110-119.
2. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-24.
3. Kyaw MH, Rose CE Jr, Fry AM, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192(3):377-386.
4. Robinson KA, Baughman W, Rothrock G, et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA. 2001;285(13):1729-1735.
5. Watt JP, O'Brien KL, Benin AL, et al. Invasive pneumococcal disease among Navajo adults, 1989-1998. Clin Infect Dis. 2004;38(4):496-501.
6. Davidson M, Schraer CD, Parkinson AJ, et al. Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. JAMA. 1989;261(5):715-718.
7. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990 - ethnic differences and opportunities for prevention. J Infect Dis. 1994;170(2):368-376.
8. Cortese MM, Wolff MM, Almeido-Hill J, Reid R, Ketcham J, Santosham M. High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. Arch Intern Med. 1992;152(11):2277-2282.
9. Siber GR, Santosham M, Reid GR, et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med. 1990;323(20):1387-1392.
10. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA. 1993;270(15):1826-1831.
11. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med. 1980;303(10):549-552.
12. Benin AL, O'Brien KL, Watt JP, et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J Infect Dis. 2003;188(1):81-89.
13. O'Brien KL, Moulton LH, Reid R, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet. 2003;362(9381):355-361.
14. Centers for Disease Control and Prevention. Active bacterial core surveillance report, Emerging Infections Program Network, Streptococcus pneumoniae, 2004. 2005. http://www.cdc.gov/ncidod/dbmd/abcs/survreports/spneu04. pdf. Accessed November 12, 2006.
15. United States Census Bureau. Census 2000 summary file 1. 2001. http://factfinder.census.gov. Accessed November 12, 2006.
16. United States Census Bureau. Census 2000 American Indian and Alaskan Native summary file. 2004. http://factfinder.census.gov. Accessed November 12, 2006.
17. Gohdes D, Kaufman S, Valway S. Diabetes in American Indians: an overview. Diabetes Care. 1993;16(1):239-243.
18. Centers for Disease Control and Prevention. National diabetes fact sheet. November 16, 2005. http://www.cdc.gov/diabetes/pubs/estimates05.htm#prev. Accessed November 12, 2006.
19. Burrows NR, Geiss LS, Engelgau MM, Acton KJ. Prevalence of diabetes among Native Americans and Alaska Natives, 1990-1997: an increasing burden. Diabetes Care. 2000;23(12):1786-1790.
20. Nuorti JP, Butler JC, Farley MM, et al; Active Bacterial Core Surveillance Team. Cigarette smoking and invasive pneumococcal disease. N Engl J Med. 2000;342(10):681-689.
21. Beauvais F. American Indians and alcohol. Alcohol Health Res World. 1998;22(4):253-259.
22. Feikin DR, Klugman KP, Facklam RR, Zell ER, Schuchat A, Whitney CG. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis. 2005;41(4):481-487.
23. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294(16):2043-2051.
24. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage among persons aged ≥65 years-United States, 2004-2005. MMWR Morb Mortal Wkly Rep. 2006;55(39):1065-1068.
25. Singleton JA, Greby SM, Wooten KG, Walker FJ, Strikas R. Influenza, pneumococcal, and tetanus toxioid vaccination of adults - United States, 1993-7. MMWR CDC Surveill Summ. 2000;49(9):39-62.
26. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med. 1984;101(3):325-330.
27. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med. 1987;83(3):425-430.
28. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med. 1988;108(5):653-657.
29. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453-1460.
30. Farr BM, Johnston BL, Cobb DK, et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch Intern Med. 1995;155(21):2336-2340.
31. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003;348(18):1747-1755.
32. Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis. 2006;43(8):1004-1008.
33. Vila-Córcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis. 2006;43(7):860-868.
34. Dominguez A, Salleras L, Fedson DS, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis. 2005;40(9):1250-1257.
35. Singleton RJ, Butler JC, Bulkow LR, et al. Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska native adults. Vaccine. 2007;25(12):2288-2295.
36. Szabo G. Consequences of alcohol consumption on host defence. Alcohol Alcohol. 1999;34(6):830-841.
37. Smith WI Jr, Van Thiel DH, Whiteside T, et al. Altered immunity in male patients with alcoholic liver disease: evidence for defective immune regulation. Alcohol Clin Exp Res. 1980;4(2):199-206.